© 2001 American Heart Association, Inc.
Thrombosis |
Comparative Antiplatelet Efficacy of a Novel, Nonpeptide GPIIb/IIIa Antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis
From the Department of Chemical Engineering (J.P.A., N.T., O.J.T.M., D.P., K.K.), Johns Hopkins University, Baltimore, Md, and DuPont Pharmaceuticals Co (S.A.M.), Wilmington, Del.
Correspondence to Konstantinos Konstantopoulos, PhD, Department of Chemical Engineering, Johns Hopkins University, 3400 N Charles St, Baltimore, MD 21218-2694. E-mail konst_k{at}jhu.edu
Abstract—Glycoprotein
(GP) IIb/IIIa is pivotal in homotypic platelet aggregation and may
also be involved in the heterotypic adhesion of leukocytes and tumor
cells to platelets. This study was primarily undertaken to compare
the antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa
antagonist, XV454, to that of abciximab in 2 flow models of
platelet thrombus formation: (1) direct shear-induced platelet
aggregation imposed by a cone-and-plate rheometer and (2) platelet
adhesion onto von Willebrand factor (vWF)/collagen I followed
by aggregation in a perfusion system. XV454 inhibited platelet
aggregation in a concentration-dependent manner in both experimental
models. Maximal inhibition of aggregation was achieved by XV454 at
70% receptor occupancy, which is lower than the 
85% previously
reported for abciximab. At similar levels of receptor blockade
(45%), XV454 appeared to be relatively more effective than
abciximab in suppressing platelet aggregation. Neither XV454 nor
abciximab inhibited platelet adhesion to collagen. Pretreatment of
surface-adherent platelets with either XV454 or abciximab inhibited
the attachment of monocytic THP-1 cells under flow. In contrast, the
rapidly reversible GPIIb/IIIa inhibitor orbofiban failed to
suppress these heterotypic interactions. These findings demonstrate
that XV454 is a potent GPIIb/IIIa antagonist with a long
receptor-bound lifetime like abciximab and may be beneficial for the
treatment/prevention of thrombotic complications.
Key Words: platelets • adhesion • aggregation • shear stress • XV454, abciximab
This article has been cited by other articles:
 |
|
 |
|
  N. Procopio Evagrio George, Q. Wei, P. Kyun Shin, K. Konstantopoulos, and J. M. Ross Staphylococcus aureus Adhesion via Spa, ClfA, and SdrCDE to Immobilized Platelets Demonstrates Shear-Dependent Behavior Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2394 - 2400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. T. McCarty, M. K. Larson, J. M. Auger, N. Kalia, B. T. Atkinson, A. C. Pearce, S. Ruf, R. B. Henderson, V. L. J. Tybulewicz, L. M. Machesky, et al. Rac1 Is Essential for Platelet Lamellipodia Formation and Aggregate Stability under Flow J. Biol. Chem., November 25, 2005; 280(47): 39474 - 39484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Burdick and K. Konstantopoulos Platelet-induced enhancement of LS174T colon carcinoma and THP-1 monocytoid cell adhesion to vascular endothelium under flow Am J Physiol Cell Physiol, August 1, 2004; 287(2): C539 - C547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pawar, P. K. Shin, S. A. Mousa, J. M. Ross, and K. Konstantopoulos Fluid Shear Regulates the Kinetics and Receptor Specificity of Staphylococcus aureus Binding to Activated Platelets J. Immunol., July 15, 2004; 173(2): 1258 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. T. McCarty, N. Tien, B. S. Bochner, and K. Konstantopoulos Exogenous eosinophil activation converts PSGL-1-dependent binding to CD18-dependent stable adhesion to platelets in shear flow Am J Physiol Cell Physiol, May 1, 2003; 284(5): C1223 - C1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Burdick, J. M. McCaffery, Y. S. Kim, B. S. Bochner, and K. Konstantopoulos Colon carcinoma cell glycolipids, integrins, and other glycoproteins mediate adhesion to HUVECs under flow Am J Physiol Cell Physiol, April 1, 2003; 284(4): C977 - C987. [Abstract] [Full Text] [PDF]
|
|